Newswise — HOUSTON & POHANG, South Korea – The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement to co-develop CBT-001,…
Read more MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapyNewswise — SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of…
Read more ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosisNewswise — SAN DIEGO ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood…
Read more ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorderNewswise — Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of…
Read more ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemiasNewswise — HOUSTON ― The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates the…
Read more MD Anderson announces Institute for Data Science in Oncology to advance mission to end cancerNewswise — MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with…
Read more ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancerNewswise — HOUSTON ― Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for…
Read more Jennifer Wargo, M.D., elected to the National Academy of MedicineNewswise — SINGAPORE ― Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation…
Read more Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancerNewswise — HOUSTON and SAN MATEO, Calif. ― The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a…
Read more MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancerNewswise — HOUSTON ― A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying from lung cancer when combined…
Read more Blood test aids in predicting lung cancer mortality riskABSTRACT: 4008 Newswise — CHICAGO ― HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas…
Read more ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancerNewswise — HOUSTON ― A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper understanding…
Read more Pan-cancer T cell atlas reveals new details of tumor microenvironmentABSTRACT: 7003 Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority…
Read more ASCO: Luspatercept enables majority of patients with MDS to end reliance on blood transfusionsNewswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made…
Read more MD Anderson Research Highlights for May 24, 2023
